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Abstract
Purpose There are risks of common bile duct (CBD)
stones in acute cholecystitis, and there is a move among
surgeons to identify choledocholithiasis before surgery.
Magnetic resonance cholangiopancreaticography (MRCP)
has the potential to accurately detect choledocholithiasis in
patients with acute cholecystitis. The aim of this study was
to evaluate the predictive values of MRCP and elevated
biochemical predictors for choledocholithiasis in patients
with acute cholecystitis.
Methods Between September 2006 and August 2008, of
84 patients with acute cholecystitis based on the diagnosis
criteria of the Tokyo guidelines, 57 had MRCP preopera-
tively. The predictive values of six biochemical predictors
for choledocholithiasis were also evaluated.
Results Of the 57 patients, seven (12.28%) had choled-
ocholithiasis, of whom three had CBD stones in nondilated
ducts. The smallest stone detected in a dilated CBD and
nondilated duct was 3.19 and 4.55 mm in diameter,
respectively. None of our patients whose MRCP showed a
clear CBD returned with symptomatic choledocholithiasis
during the follow-up period. All biochemical predictors
and CBD diameter had limited positive predictive values.
Conclusions Magnetic resonance cholangiopancreatico-
graphy is a reliable evaluation technique for the detection
of choledocholithiasis. It reduces the misdiagnosis of
retained choledocholithiasis with normal biochemical pre-
dictors and prevents the risk of overlooking choledocholi-
thiasis. No single predictor or combined markers have been
found to be reliable for including/excluding the presence of
choledocholithiasis.
Keywords Magnetic resonance
cholangiopancreatography  Acute cholecystitis 
Choledocholithiasis  Liver enzymes  Ultrasonography
Introduction
Of patients undergoing cholecystectomy for cholelithiasis,
3–33% will also harbor common bile duct (CBD) stones [1,
2], and the incidence of those with symptoms suggestive of
choledocholithiasis will be even higher. Risk factors for
choledocholithiasis are well recognized [3], and there is a
move among clinicians to identify CBD stones before sur-
gery. The serum hepatobiliary biochemical index and find-
ings on abdominal ultrasonography images have commonly
been used to initially predict CBD stones [1–6]. However,
the biochemical predictive models may be affected by
inflammatory gallstone disease due to abnormally elevated
predictor levels secondary to acute transient hepatocellular
injury [7], thus disguising biliary obstruction owing to CBD
stones. In addition, the low accuracy of ultrasonography in
early extrahepatic obstruction [6, 8] limits its reliability in
predicting the necessity for CBD exploration. Magnetic
resonance cholangiopancreaticography (MRCP) is a non-
invasive technique that has the potential to accurately eval-
uate choledocholithiasis in the preoperative acute calculous
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cholecystitis setting. Although MRCP is reportedly begin-
ning to replace diagnostic endoscopic retrograde cholangi-
opancreatography (ERCP) for the early assessment of
suspected biliary obstruction due to its comparable accuracy
[9], its cost-effectiveness is still under debate. In cases of
acute cholecystitis, we routinely investigate biliary demo-
graphics preoperatively using medical imaging, mostly with
MRCP. The aims of the study reported here were to evaluate
the predictive value of elevated hepatobiliary biochemical
predictors for CBD stones and the influence of the MRCP
results on perioperative management.
Materials and methods
This study was conducted in an urban university teaching
hospital that provides surgical services and primary, sec-
ondary, and tertiary care. Eighty-four patients diagnosed
with acute cholecystitis based on the diagnostic criteria of
the Tokyo guidelines for acute cholecystitis [10] between
September 2006 and August 2008 were identified. In our
department, all patients routinely undergo MRCP, abdom-
inal computed tomography (CT), ERCP, or percutaneous
transhepatic gallbladder drainage (PTGBD) tube-cholangi-
ography preoperatively to demonstrate the complete biliary
anatomy. The surveys of those who had only preoperative
abdominal CT, ERCP and/or post-PTGBD tube-cholangi-
ography were excluded from our study.
MRCP scans were performed on a Siemens 1.5T Mag-
netom Sonata scanner (Siemens, Munich, Germany) using
a T2-weighted Turbo Spin Echo sequence acquired with a
non-breath-hold in the coronal plane. On hospital admis-
sion, blood samples were collected for the laboratory
analysis of serum hepatobiliary biochemical predictor
levels prior to the MRCP. The abnormal cut-off levels were
as follows: aspartate aminotransferase (AST [38 U/L),
alanine aminotransferase (ALT [37 U/L), total bilirubin
(TB [1.2 mg/dL), direct bilirubin (DB [0.2 mg/dL),
alkaline phosphatase (ALP [122 U/L), and gamma glut-
amyl transferase (GGT[49 U/L). The clinical definition of
the presence/absence of CBD stones is based on the iden-
tification of CBD stones on the MRCP. Patients with CBD
stones detected on the MR image were managed preoper-
atively with ERCP. The treatment choices were given by
one surgeon who used consistent criteria for the assignment
of patients to specific courses of treatment according to the
Tokyo guidelines for biliary infection. Intraoperative ultr-
asonographic cholangiography was used to confirm the
patient free of CBD stones. All patients were advised to
consult the authors if they developed symptoms such as
abdominal pain, fever, nausea, vomiting, anorexia, or
jaundice. The ambulatory follow-up was conducted for at
least 12 months
All statistical analyses were performed with SPSS for
Windows ver. 12.0 (SPSS, Chicago, IL). Test characteris-
tics were determined for all clinical parameters (CBD size
on the MR image, CBD size on the ultrasonographic
image, serum hepatobiliary biochemistry examination),
including sensitivity, specificity, likelihood ratio, preva-
lence, accuracy, positive predictive values, and negative
predictive value for each potential parameter for CBD
stones. The CBD diameter based on the MRCP was ana-
lyzed categorically using subjective assessments of
enlargement and a cut-off value of [10 mm. The Fisher’s
exact test was used to determine the clinical variables
associated with the presence of CBD stones. A p value of
\0.05 was considered to be statistically significant. All
significant factors from the univariate analysis were sub-
sequently included in the multivariate analysis, which was
carried out by logistic regression to determine the inde-
pendent parameter.
Results
In this study, 57 MRCP examinations were performed prior
to a cholecystectomy. All patients who underwent MRCP
examinations were included in the analysis. The mean age
of the patient cohort was 55.79 ± 14.66 (range
26.33–81.19) years, and 49.12% (n = 28) of the patients
were women (Table 1).
Of the 84 patients diagnosed with acute cholecystitis
during the study period, 12 (14.28%) had CBD stones, and
only eight of the latter had jaundice. Of the 57 enrolled
participants (with MRCP examinations), jaundice was
identified in three patients with CBD stones and in 21
patients without. Of the seven patients with stones
detected by MR, one patients had all normal biochemical
predictors; in comparison, 14 patients without
Table 1 Demographic findings
Characteristics Total CBD stones (?) CBD stones (-)
Sex (male:female) 29:28 5:2 24:26
Age (years)
C55 32 6 26
\55 25 1 24
American Society of Anesthesiologists physical status
BII 45 5 40
[II 12 2 10
Tokyo guideline severity assessment
Mild 30 3 27
Moderate 23 4 19
Severe 4 0 4
CBD Common bile duct
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choledocholithiasis had normal serum biochemical levels.
According to the diagnostic criteria of the Tokyo guide-
lines for acute cholangitis, an elevated serum hepatobiliary
index is also suitable for making the diagnosis of acute
cholangitis. It would have been dangerous to have defined
the patient with a positive MR for CBD stones but normal
biochemical predictors as having a silent stone, as the
patient was symptomatic with proven systemic inflam-
mation at admission.
All patients had a cholecystectomy at a mean of
3.35 days post-MRCP (range 0–17 days), mainly laparo-
scopically. Fifty-two patients underwent a laparoscopic
cholecystectomy with a conversion rate of 6.12%. Five
patients had an open cholecystectomy because of previous
upper abdominal surgery. Our patients had a mean post-
operative hospitalization stay of 2.96 (range 1–8) days.
MRCP findings
The MRCP results were positive for CBD stones in seven of
the 57 patients (12.28%) (four with a single stone; three
with multiple stones); six of these seven patients were
[55 years of age. The stones ranged in maximum diameter
from 3.19 to 9 mm (mean 6.47 mm), whereas the diameter
of the bile ducts ranged from 5.07 to 21.05 mm (mean
9.07 mm). In three patients, the stones were located in a
nondilated duct. The smallest stone detected with MRCP
had a diameter of 3.19 mm and was located in a dilated
extrahepatic bile duct (Fig. 1a, diameter 11.53 mm). The
smallest stone located in a nondilated duct (Fig. 1b, diam-
eter 7.74 mm) was 4.55 mm in diameter. All seven patients
with stones detected by MR were further proven and man-
aged preoperatively with ERCP, which the absence of false
positive; the overall specificity of MRCP was 100%. The
possibility of CBD sludge or undetectable stones smaller
than 3 mm is always taken into account. A false negative of
such small debris may exist, but spontaneous evacuation of
such debris can be expected and further postoperative fol-
low-up is necessary. The fact that none of our patients
whose MRCP showed a clear CBD returned with symp-
tomatic CBD stones at the clinical follow-up 1 week and a
year after discharge also demonstrated the overall high
sensitivity of MRCP.
Description of clinical predictors
The frequency and mean serum levels of the different
parameters are shown in Table 2. Mean CBD diameters
based on the MRCP findings were 12.55 (range
7.74–21.05) mm for patients with acute cholecystitis with
choledocholithiasis and 8.59 (range 5.07–13.72) mm for
patients without CBD stones. In 23% (n = 13) of our
patients, the CBD could not be fully observed; in none of
the patients were CBD stones directly identified based on
transabdominal ultrasonography findings. The diameter of
the ultrasonographically detected bile ducts ranged from 5
Fig. 1 Magnetic resonance
cholangiopancreaticography
(MRCP) image demonstrates
common bile duct (CBD)
calculi (arrows). a T2-weighted
short echo time sequence (TR/
TE 2000/79 ms, slice thickness
5 mm, scan time 3 min 44 s).
The smallest stone was
3.19 mm in a dilated CBD.
b T2-weighted turbo spin-echo
sequence (TR/TE 1800/635 ms,
slice thickness 1.15 mm, scan
time 3 min 44 s). The smallest
stone in a nondilated duct was
4.55 mm in diameter
Table 2 Patients with dilated CBD and abnormal serum biochemical
parameters
Component Mean (range) Abnormal results/
no. of patients
MR CBD size (mm) 9.08 (5.07–21.05) 14/57
U/S CBD size (mm) 7.99 (5.00–14.00) 10/44
AST (U/L) 28.98 (10–105) 11/56
ALT (U/L) 45.75 (7–172) 24/57
TB (mg/dL) 1.34 (0.4–8) 24/57
DB (mg/dL) 5.95 (0–3.9) 15/26
ALP (U/L) 109.29 (35–407) 16/56
GGT (U/L) 133.04 (1.4–1141) 17/34
AST Aspartate aminotransferase, ALT alanine aminotransferase, TB
total bilirubin, DB direct bilirubin, ALP alkaline phosphotase, GGT
gamma glutamyl transferase, MR magnetic resonance cholangiopan-
creaticography, U/S transabdominal ultrasonography
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to 14 (mean 8) mm, with a mean bile duct diameter of
10.2 mm (n = 6) in choledocholithiasis patients and
7.6 mm (n = 39) in patients without CBD stones. Mea-
surements of the diameter of the bile duct based on MRCP
and transabdominal ultrasonography were found to be
similar in terms of diagnostic accuracy in predicting CBD
stones (Table 2), with low sensitivities of 57% [95% con-
fidence interval (CI) 20–94] and 50% (95% CI 10–90),
respectively. Among the six biochemical predictors, ALT,
GGT, and DB had the highest sensitivity at 86, 83, and
80%, respectively. The specificity was highest for AST
(86%) and ALP (76%). All biochemical predictors had a
limited positive predictive value, while ALT, ALP, and
AST had the highest negative predictive value at 97%
(95% CI 91–100), 95% (95% CI 88–100), and 93% (95%
CI 86–100), respectively.
Accuracy of the clinical parameters
Table 3 shows the analysis of the predictors of CBD
stones. Both CBD diameter and elevated serum biochem-
ical parameters were found to have only a limited positive
predictive value for the presence of CBD stones. Among
the six non-invasive biochemical markers evaluated in our
study, the analysis of each predictor revealed that elevated
AST, ALT, and ALP were statistically significant predic-
tors. Multiple logistic regression analysis of these three
predictors revealed that they were not jointly significant:
AST, 1.78 (95% CI 0.21–14.85); ALT, 5.25 (95% CI
0.43–63.45); ALP, 3.46 (95% CI 0.47–25.24). A backward
stepwise logistic regression model was created with the
presence or absence of CBD stones as the dependent var-
iable and the previously determined statistically significant
variables (AST, ALT, and ALP) as independent variables.
The backward stepwise model begins with all factors
entered in the model and then removes nonsignificant
factors in a stepwise fashion, such that only statistically
significant factors are retained in the final model. In the
final model, ALT [odds ratio (OR) 9.412, 95% CI
1.02–87.19, p = 0.048] was a significant predictor. As
mentioned above, the false negative of MRCP undetectable
sludge or small debris might be possible. The potential for
a degree of error in the accuracy of CBD size and bio-
chemical predictors does exist because the data for the
calculations on biochemical predictor sensitivities and
specificities originate from a pool of patients who had
MRCP-based findings by virtue of the enrolment criteria.
Follow-up of patients and prognosis
Patients were advised to consult us if they developed
symptoms such as abdominal pain, fever, nausea, vomiting,
anorexia, or jaundice, and the ambulatory follow-up was
conducted for at least 12 months. However, only 96.49%
(n = 55) of the 57 patients returned to the clinic for the
1-week postoperative follow-up, and only 43.86%
(n = 25) returned for the 12-month follow-up.
The mean period of postoperative follow-up was
9.09 months (range 5 days to 45.30 months). During the
follow-up period, the following clinical symptoms were
observed: surgical site infection (6 patients, 10.5%),
umbilical hernia (1 patient, 1.7%), diarrhea (1 patient,
1.7%), and postoperative cholangitis (1 patient, 1.7%) that
occurred 6 months postoperatively. In the latter case, the
patient was admitted to hospital for 1 week where there was
a good response to medical treatment. In the follow-up
period, a retained CBD stone was found in one of the
patients with CBD dilation 12 months postoperatively. The
patient had had preoperative endoscopic stone removal
following the identification of CBD stones by MR (MR
CBD size 16.44 mm; multiple stones size of 3.09 and
8.50 mm, respectively), and all preoperative biochemical
predictors were normal. As a result, postoperative ERCP
was performed in only one case.
Table 3 Predictors of common bile duct stones in patients with acute cholecystitis undergoing magnetic resonance cholangiopancreaticography
Clinical predictors Sensitivity (%) Specificity (%) Likelihood ratio PPV NPV p value
MR CBD size (n = 57) 57 (20–94) 80 (69–91) 2.86 (1.22–6.67) 29 93 0.0541
U/S CBD size (n = 44) 50 (10–90) 82 (69–94) 2.71 (0.96–7.70) 30 91 0.1197
AST (n = 56) 57 (20–94) 86 (76–96) 4.00 (1.56–10.23) 36 93 0.0223
ALT (n = 57) 86 (60–100) 64 (51–77) 2.38 (1.48–3.84) 25 97 0.0343
Total bilirubin (n = 57) 43 (6–80) 58 (44–72) 1.02 (0.41–2.55) 13 88 1
Direct bilirubin (n = 26) 80 (45–100) 48 (26–69) 1.53 (0.84–2.78) 27 91 0.3562
ALP (n = 56) 67 (29–100) 76 (64–88) 2.78 (1.31–5.88) 25 95 0.0494
GGT (n = 34) 83 (54–100) 57 (39–75) 1.94 (1.11–3.4) 29 94 0.1748
Sensitivity, specificity, and likelihood ratio are given as a percentage, with the 95% confidence intervals (95% CIs) given in parentheses
PPV Positive predictive value, NPV negative predictive value
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Discussion
The probability of a patient having CBD stones should be
stratified on the basis of clinical, biochemical, and radio-
logical parameters into low and high risk groups for CBD
stones, which can then dictate further work-up and man-
agement. However, the ‘‘a priori’’ probability of CBD
stones is difficult to assign and, therefore, it is not easy to
estimate the specific risk to an individual patient.
Eighty-four patients diagnosed with acute cholecystitis
were identified in this study according to the diagnostic
criteria of the Tokyo guidelines for cholecystitis. Based on
the strength and quality of the diagnostic evidence, all our
reported patients with acute cholecystitis were admitted to
the surgical service by the same surgeon in our hospital. A
number of published studies have combined data from
patients with acute cholecystitis with those having simple
acute biliary colic. These are two different entities, with
each having a different incidence of CBD stones; conse-
quently, they should be discussed separately. In 2005, Peng
et al. reported that of 243 acute biliary colic cases and 142
acute cholecystitis patients, all of whom had had a prior
laparoscopic cholecystectomy, 7.7 and 16.5% had choled-
ocholithiasis, respectively [11]. Nebiker et al. [12] also
reported that patients with cholecystitis had a higher fre-
quency of CBD stones (9.1%) than those without signs of
acute inflammation (6.6%), which motivated us to analyze
patients with acute calculous cholecystitis. The inflamma-
tory process may also result in elevated serum biochemical
predictor levels secondary to acute transient hepatocellular
injury, thereby interfering with the accuracy by which
serum biochemical predictors can be used to detect CBD
stones [7]. Based on our limited number of patients, we
found that patients testing positive for CBD stones in the
biochemical tests did not necessarily present more severe
clinical symptoms according to Tokyo guideline classifi-
cation of severity.
Although serum biochemical predictors have been
reported to be reliable for use as an initial screening
modality, the specific biochemical predictors reported to be
accurate and their cut-off levels vary from institution to
institution [1–3, 5]. Our recommended time interval for a
cholecystectomy is within 96 h after presentation of initial
symptoms; consequently, blood samples are collected upon
admission to enable the laboratory analysis of serum he-
patobiliary biochemical predictor levels. The univariate
analysis carried out in our study demonstrated that AST,
ALT, and ALP are independent noninvasive predictors for
the detection of CBD stones. In the final backward stepwise
logistic regression model, ALT was found to be the only
significant predictor. When all three predictors were
entered into the model, the analysis revealed that the three
predictors were not jointly significant statistically. In terms
of cost-effectiveness, ALT is noted to be the most cost-
effective of probability markers of CBD stones, and the
utility of all three predictors in the detection of CBD stones
may carry a higher risk of overlooking CBD stones. As a
result, no single predictor or combined markers have been
found to be reliable enough to be used to include or exclude
the presence of CBD stones.
All patients had preoperative transabdominal ultraso-
nography, which has been reported to be a reliable
screening modality in terms of CBD stone detection.
However, this technique often provides only limited or
indirect CBD data and only rarely enables the direct
inspection of CBD stones [8]. The CBD was undetectable
in about 25% of our patients, and transabdominal ultraso-
nography was unable to directly identify CBD stones in
any of our patients. Some reports emphasize that about
one-third of CBD stones detected ultrasonographically
occur in nondilated biliary systems [13, 14], which can be
easily missed [15]. Ultrasonography is also reported to be
less sensitive for choledocholithiasis, with a sensitivity
ranging from 12 to 55% [16]. However, CT is unlikely to
provide more information than ultrasonography in cho-
ledocholithiasis [8]. Of the 57 patients testing negative for
CBD stones, nine also had a preoperative CT that showed a
mean CBD diameter of 10.21 mm (range 7.33–12.41 mm),
which was relatively larger than the measurements calcu-
lated on the basis of MRCP measurements. In addition to
the 57 patients who underwent a MRCP, other subjects
were examined with different isolated investigative
modalities, such as CT (n = 26), percutaneous cholangi-
ography (PTC) (n = 19), and ERCP (n = 12); the data on
these patients were excluded from this study—mainly
because ERC and PTC are considered to be invasive
techniques and limited to therapeutic purposes. It should be
possible to predict CBD stones using noninvasive tests that
avoid unnecessary and risky procedures. The accuracy of
CT in diagnosing CBD stones remains a challenge, with a
reported sensitivity varying from 50 to 90% [17, 18], as
only calcified stones can be visualized and cholesterol
stones can have the same density as bile [19].
MR imaging (MRI) was first applied in 1986 for the
diagnosis of biliary disease, demonstrating only the anat-
omy of the dilated bile ducts and the location of an
obstruction [20]. With advances in technology and the
refinement of MR cholangiographic sequences, MRI has
become a more reliable diagnostic tool for detecting CBD
stones [21], although the presence of CBD sludge or
undetectable stones \3 mm in diameter remains unknown
and the spontaneous passage of such small debris is pos-
sible [22, 23]. Not one patient whose MRCP showed a
clear CBD returned with symptomatic CBD stones at the
clinical follow-up 1 week and a year after discharge, which
suggests a high negative predictive value for the MRCP
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and intraoperative ultrasonography. All cholecystecto-
mized patients in this study were confirmed to be free of
CBD stones by intraoperative ultrasonographic cholangi-
ography. CBD stones were found in seven of the 57
patients (12.28%) (four with single stones; three with
multiple stones). The stones ranged in diameter from 3.19
to 9.0 (mean 6.47 mm) mm, whereas the diameter of the
bile ducts ranged from 5.07 to 21.05 mm (mean 9.07 mm).
The patients with CBD stones had a wider MR bile duct
mean diameter (12.55 mm) than those without CBD stones
(8.59 mm). However, the location of the CBD stones in
three patients was in a nondilated duct that could be missed
by an over-dependence on the predictor of common duct
diameters. The smallest stone detected with MRCP was
3.19 mm in diameter and was located in a dilated extra-
hepatic bile duct; the smallest stone detected in a nondi-
lated duct was 4.55 mm in diameter. A prospective study
of 265 patients by Fulcher et al. [24] showed a sensitivity
of 100% and a specificity of 98–100%, with excellent
resolution of MRCP for the detection of CBD stones: the
calculi detected range from 2 to 20 mm in diameter
(average diameter 9 mm).
MRCP is a reliable and noninvasive procedure for
detecting or excluding the presence of CBD stones [25, 26].
It also has the potential to reduce the number of invasive
preoperative diagnostic procedures [27, 28] and their
associated risks and overall healthcare costs [29]. MRCP
can also allow the surgeon to verify the state of the patient’s
biliary ductal demographic condition, and even in severe
inflammation cases the cystic duct can be cannulated more
confidently based on a more thorough understanding of a
specific patient’s characteristics preoperatively [12]. Severe
inflammation is reported as one of the most important
reasons for bile duct injury [30], as the presence of
inflammation in the acute setting may obscure the view of
Calot’s triangle.
Surgeons are usually more skilled in using an imaging
modality to exclude the presence of CBD stones; however,
an MRI is usually not recommended for this purpose due
to economic considerations [12]. There is some evidence
that MRCP is more accurate than a diagnostic ERCP,
although the quality of these studies has been criticized
[31]. As MRCP yields only static reconstructed images,
our measurements of the size of the CBD based on MRI
findings may be less accurate than those based on diag-
nostic ERCP findings. ERCP is still considered to be the
‘gold standard’ for the diagnosis of pancreatic and biliary
ductal pathology [32]. In addition to medical consider-
ations, we must also consider the costs, and although the
costs of diagnostic modalities differ markedly by country
and by healthcare system, transabdominal ultrasound
and serum biochemical predictors are universally less
expensive than MRCP.
Conclusion
Magnetic resonance cholangiopancreaticography is a reli-
able and noninvasive evaluation for the detection or
exclusion of CBD stones. Rather than indicating a need for
CBD exploration, MRCP is more useful in determining
when not to explore and for avoiding retained CBD stones
in small CBD. No single predictor or combined markers
have been found to be the best evidence to include or
exclude the presence of CBD stones if the stone is directly
inspected by cholangiography.
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